Value
8.3/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.4 |
| P/S | 9.0 |
| EV/EBITDA | 6.0 |
| Fwd P/E | 9.7 |
| PEG | 10.0 |
| Analyst target | 7.5 |
- ▸Forward P/E: 7.2x
- ▸PEG: 0.08
- ▸Attractively valued
ANIP · Why this verdict
Why ANI Pharmaceuticals (ANIP) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
ANI Pharmaceuticals offers an attractively valued specialty pharmaceutical franchise trading at 7.7x forward earnings with a PEG of 0.09, free cash flow exceeding net income by 52%, and four consecutive earnings beats averaging a 29% positive surprise — yet near-term positioning is constrained by an 18% short interest, a failed critical filing gate, and single-source supplier concentration across key product lines.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has delivered four consecutive quarterly earnings beats with an average positive surprise of roughly 29%, including a most recent quarterly result that exceeded consensus by 58%, reflecting a pattern of consistently under-promising and over-delivering on financial guidance. Earnings | EPS surprise remains above 10% for at least 3 of the next 4 reported quarters. | ↑Improving |
| CounterAn 18% short interest reflects meaningful institutional skepticism that the earnings pace is sustainable; a single miss after four clean beats could sharply reprice the stock given implied volatility near 72%. | ||
At a forward price-to-earnings of 7.7x with a PEG ratio of 0.09 and revenue growing near 20% annually, the stock appears materially underpriced relative to its growth rate, with analyst consensus implying roughly 37% additional upside from current levels. Valuation breakdown | Price closes above $98 within 12 months as the valuation discount narrows toward analyst targets. | Tripped→Stable |
| CounterLight analyst coverage (approximately 7 analysts) dampens the reliability of the consensus target, and the recent critical filing event that blocked a key gate may suppress institutional re-rating until the disclosure is fully resolved. | ||
Free cash flow exceeds reported net income by 52%, demonstrating that accounting earnings are fully backed by real cash generation, supported by a near-perfect Piotroski financial health score of 8 out of 9. Quality breakdown | Free cash flow continues to exceed net income (FCF-to-net-income ratio stays above 100%) for each of the next 4 quarters. | →Stable |
| CounterA debt-to-equity ratio of 1.1 and high-severity single-source supplier dependencies across key contract manufacturers mean that any supply disruption could simultaneously compress cash flows and tighten the leverage cushion. | ||
With roughly 18% of the float sold short against a business delivering consistent earnings beats, conditions are in place for a short-covering rally if operational momentum continues — a technical dynamic that could amplify price appreciation beyond what fundamentals alone would imply. Risk breakdown | Short interest declines below 10% over the next 12 months as the earnings record forces bears to cover. | ↑Improving |
| CounterA put/call ratio of 1.33 and implied volatility near 72% indicate the market is pricing in genuine downside risk, not indiscriminate speculation; the failed critical filing gate may represent the concrete risk that bears are positioned to exploit. | ||
The company has delivered four consecutive quarterly earnings beats with an average positive surprise of roughly 29%, including a most recent quarterly result that exceeded consensus by 58%, reflecting a pattern of consistently under-promising and over-delivering on financial guidance.
↑ImprovingEarnings
- Expectation
- EPS surprise remains above 10% for at least 3 of the next 4 reported quarters.
CounterAn 18% short interest reflects meaningful institutional skepticism that the earnings pace is sustainable; a single miss after four clean beats could sharply reprice the stock given implied volatility near 72%.
At a forward price-to-earnings of 7.7x with a PEG ratio of 0.09 and revenue growing near 20% annually, the stock appears materially underpriced relative to its growth rate, with analyst consensus implying roughly 37% additional upside from current levels.
Tripped→StableValuation breakdown
- Expectation
- Price closes above $98 within 12 months as the valuation discount narrows toward analyst targets.
CounterLight analyst coverage (approximately 7 analysts) dampens the reliability of the consensus target, and the recent critical filing event that blocked a key gate may suppress institutional re-rating until the disclosure is fully resolved.
Free cash flow exceeds reported net income by 52%, demonstrating that accounting earnings are fully backed by real cash generation, supported by a near-perfect Piotroski financial health score of 8 out of 9.
→StableQuality breakdown
- Expectation
- Free cash flow continues to exceed net income (FCF-to-net-income ratio stays above 100%) for each of the next 4 quarters.
CounterA debt-to-equity ratio of 1.1 and high-severity single-source supplier dependencies across key contract manufacturers mean that any supply disruption could simultaneously compress cash flows and tighten the leverage cushion.
With roughly 18% of the float sold short against a business delivering consistent earnings beats, conditions are in place for a short-covering rally if operational momentum continues — a technical dynamic that could amplify price appreciation beyond what fundamentals alone would imply.
↑ImprovingRisk breakdown
- Expectation
- Short interest declines below 10% over the next 12 months as the earnings record forces bears to cover.
CounterA put/call ratio of 1.33 and implied volatility near 72% indicate the market is pricing in genuine downside risk, not indiscriminate speculation; the failed critical filing gate may represent the concrete risk that bears are positioned to exploit.
Per-dimension breakdown
Quality
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 6.1 |
| ROA | 3.3 |
| Gross margin | 8.2 |
| Op margin | 6.5 |
| Net margin | 5.0 |
| Current ratio | 9.9 |
| FCF quality | 10.0 |
| Moat | 6.9 |
| Piotroski F | 8.9 |
- ▸Excellent cash conversion: 152% FCF/NI
- ▸Strong Piotroski F-Score: 8/9
Growth
8.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 7.6 |
| EPS growth | 10.0 |
- ▸Strong growth: 20% YoY
Momentum
1.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Capitulation risk (RSI 28, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -2.2%/30d — confirmed downtrend
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 2.0 |
| Analyst rating | 6.8 |
| Price target | 9.2 |
- ▸LLM news sentiment: -0.60 (n=3)
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 40%
Insider
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Notable insider selling — $6,482,854 (0.367% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.7 |
| quality rank | 7.0 |
| growth rank | 7.2 |
Technical
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.2 |
| support resistance | 7.9 |
| 52w position | 5.8 |
Risk (lower is worse)
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.0 |
| days to cover | 0.0 |
| volatility | 4.1 |
| put call | 6.7 |
| implied vol | 3.7 |
| beta | 10.0 |
| debt equity | 4.8 |
- ▸Short squeeze setup: 18% short, quality 7.5
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 14 days
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD|L3:NEWS_MOD=+1|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (3)
- ASYMMETRY:3.2>=1.5
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (5)
- MOMENTUM:1.0<4.5
- INSIDER:0.37%=HEAVY
- DEATH_CROSS:HARD_BLOCK
- 8K_CRITICAL:4.01
- NEWS:LEGAL
Warning (1)
- EARNINGS_PROXIMITY:14d<=14d (soft)
Reward-to-Risk
3.23
Upside
+21.7%
Downside
6.7%
Sizing output
STARTER
SetupFalling Knife — Death cross, below all MAs, RSI 28, MACD bearish
EdgeCatalyst-Driven — Earnings in 14d with 4/4 beat streak
SuitabilityAggressive — MCap $1.8B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: ASYMMETRY:3.2>=1.5. Top dim: Growth at 8.8; weakest: Momentum at 1.0. No conviction either direction.
The strongest dimensions are Growth at 8.8, Value at 8.3, and Catalyst at 7.9; the weakest are Momentum at 1.0, Risk (lower is worse) at 5.3, and Peer rank at 5.5. The V9 engine flagged 5 failed gates with 1 warning, producing an asymmetric reward-to-risk of 3.23 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Outperformance
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Attractive Valuation Growth PremiumTripped
Trip ifForward P/E multiple expands above 15x without a corresponding increase in consensus earnings estimates.
- P3Superior Cash Conversion Quality
Trip ifFree cash flow falls below net income (FCF-to-net-income ratio drops below 100%) for 2 consecutive quarters.
- P4Elevated Short Interest Squeeze Setup
Trip ifEPS surprise falls below -10% for 2 consecutive quarters, validating the core bear thesis driving short interest.